BioSpace News Archive

Oregon Bioscience Association announced the appointments of Peter Barr-Gillespie, Ph.D., Heather Ellis, Ritchard Englehardt, M.A., Tina Guldberg, Lisa Hale, Sean McClain, Todd Predmore, and Sandra Shotwell, Ph.D., to its board.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics announced that Aron Knickerbocker, Chief Executive Officer, is scheduled to present at the following investor conference.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2019 financial results on Wednesday, August 7, 2019 after the U.S. financial markets close.

TCR2 Therapeutics Inc. (Nasdaq: TCRR), today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the use of TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuCTM-T cells) as a cancer therapeutic agent against mesothelin in the Company’s ongoing Phase 1/2 trial of TC-210.

Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended June 30, 2019 and provide an operational update after market close on Wednesday, August 7, 2019.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced that Jim Hollingshead, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately.

CONMED Corporation announced financial results for the second quarter of 2019.

AngioDynamics, Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced the appointment of Karen Licitra to its board of directors as a Class III director, effective July 17, 2019.

Vertex Pharmaceuticals Incorporated reported consolidated financial results for the second quarter ended June 30, 2019 and increased its full-year 2019 total product revenue guidance.

Hologic, Inc. announced the Company’s financial results for the fiscal third quarter ended June 29, 2019.